C5a, Human, ELISA kit

C5a plays a pivotal role in the complement system, a key player in innate immunity. During the activation of complement protein 5 (C5), C5a, a potent anaphylatoxin comprising 74 amino acids, is produced. Initially short-lived, C5a is swiftly transformed in serum into the more stable C5a-desArg, maintaining biological activity and providing a reliable measure of complement activation levels in various samples. C5a exerts profound physiological effects, inducing smooth muscle contraction, vasodilation, increased vascular permeability, and inflammatory mediator release from basophils and mast cells. It also serves as a chemotactic agent, drawing eosinophils, basophils, and monocytes to
sites of inflammation.

The clinical relevance of C5a extends to inflammatory responses in conditions like gramnegative bacterial sepsis, trauma, ischemic heart disease, post-dialysis syndrome, and autoimmune diseases. Elevated C5a levels have been associated with increased cardiovascular risk and the capillary leak syndrome following bone marrow transplantation.

Notably, C5a is a significant urinary biomarker for imminent acute graft rejection post-kidney transplantation. Employing a specialized monoclonal antibody that recognizes a unique neo-epitope on C5adesArg, the human C5a ELISA kit is designed for precision, eliminating the chance of crossreactivity with C5. This precision positions the C5a ELISA kit as an essential tool for researchers delving into the complement system’s intricacies.